Retrospective Study
Copyright ©The Author(s) 2019.
World J Clin Cases. May 26, 2019; 7(10): 1111-1121
Published online May 26, 2019. doi: 10.12998/wjcc.v7.i10.1111
Table 1 Demographic data and clinical characteristics of patients with ventilator-associated pneumonia due to colistin-resistant and colistin-susceptible Acinetobacter baumannii- calcoaceticus complex
VariableTotal, n = 124CRABC group, n = 16CSABC group, n = 108P-value
Male sex (%)63 (50.8)13 (81.3)50 (46.3)0.019
Age, med ± (min-max)73.0 ± (18-91)59.5 ± (18-86)74.0 ± (18-91)0.022
Comorbidity
Diabetes mellitus (%)35 (28.2)5 (31.5)30 (27.8)0.771
Chronic renal failure (%)11 (8.9)0 (0.0)11 (10.2)0.356
Chronic obstructive lung disease (%)33 (26.6)4 (25.0)29 (26.9)1.000
Hypertension (%)57 (46.0)8 (50.0)49 (45.4)0.938
Congestive heart failure (%)25 (20.2)4 (25.0)21 (19.4)0.738
Malignity (%)30 (24.2)2 (12.5)28 (25.9)0.353
Cerebrovascular disease (%)24 (19.4)1 (6.3)23 (21.3)0.305
Trauma (%)8 (6.5)3 (18.8)5 (4.6)0.066
Operation (%)24 (19.4)2 (12.5)22 (20.4)0.735
Immunosuppression (%)9 (7.3)1 (6.3)8 (7.4)1.000
Obesity (%)12 (9.7)3 (18.8)9 (8.3)0.186
Duration of mechanical ventilation before diagnosis, med ± min-max11 ± (2-450)12 ± (4-50)11 ± (2-450)0.872
Total length of ICU stays, med ± min-max45.5 ± (5-540)49.0 ± (11-305)43.0 ± (5-540)0.685
Central venous catheterization (%)67 (54.0)9 (56.3)58 (53.7)1.000
Urethral catheterization (%)114 (91.9)14 (87.5)100 (92.6)0.616
Total parenteral nutrition (%)21 (16.9)6 (37.5)15 (13.9)0.030
Prior receipt of colistin (%)11 (8.9)6 (37.5)5 (4.6)0.001
Prior receipt of carbapenems (%)68 (54.8)10 (62.5)58 (53.7)0.696
Prior receipt of linezolid (%)6 (4.8)1 (6.3)5 (4.6)0.571
Prior receipt of ampicillin/sulbactam (%)19 (15.3)1 (6.3)18 (16.7)0.462
Prior receipt of flouroquinolones (%)51 (41.1)5 (31.3)46 (42.6)0.556
Prior receipt of teicoplanin (%)25 (20.2)6 (37.5)19 (17.6)0.091
Prior receipt of piperacillin/tazobactam (%)19 (15.3)1 (6.3)18 (16.7)0.462
Prior receipt of ceftriaxone (%)9 (7.3)0 (0.0)9 (8.3)0.603
Presence of bacteremia (%)3 (2.4)2 (12.5)1 (0.9)0.044
APACHE II scores, med ± min-max14. 0 ± (5-28)22.5 ± (17-28)12.0 ± (5-22)< 0.001
SOFA scores, med ± min-max9.0 ± (3-20)9 ± (7-18)9 ± (3-20)0.546
Clinical response (%)71 (61.3)11 (68.8)65 (60.2)0.703
Laboratory response (%)82 (66.1)13 (81.3)69 (63.9)0.277
Radiological response (%)65 (52.4)10 (62.5)55 (52.9)0.551
Microbiological response (%)67 (54.0)9 (56.3)58 (53.7)1.000
Duration of microbiological cure, med ± (min-max)4 ± (2-10)6 ± (3-10)3 ± (2-7)<0.001
In-hospital mortality (%)77 (62.1)6 (37.5)71 (65.7)0.058
VAP-related mortality (%)50 (40.3)5 (31.3)45 (41.7)0.603